An international interdisciplinary team of researchers, including Moffitt Cancer Center’s Tiffany Carson, Ph.D., has been selected to receive a Cancer Grand Challenges award.
Alex Jaeger, Ph.D., assistant member of the Molecular Oncology Department at Moffitt Cancer Center, has received a Damon Runyon-Rachleff Innovation Award. He is the first researcher in Florida and at Moffitt to earn this prestigious grant.
The kidneys are two bean-shaped organs located just below the rib cage, one on each side of your spine. Healthy kidneys filter blood to remove waste and extra water to make urine. Kidney cancer, also known as renal cell carcinoma or RCC, forms when healthy cells in one or both kidneys grow out of control. Learn more with Dr. Saum Ghodoussipour from Rutgers Cancer Institute of New Jersey.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media team to set up interviews.
Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, the state’s leading cancer center and only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has scored in the “exceptional” range and was redesignated by the National Cancer Institute, placing it among the top cancer centers reviewed in 2023.
Florette K. Gray Hazard, a pediatric pathologist, has been appointed chair of the Department of Pathology and Laboratory Sciences at the UC Davis School of Medicine. She will lead a department with 50 faculty, 16 residents, and more than 400 academic and clinical staff.
Pool Cool is a program designed to educate young people in The University of Kansas Cancer Center’s catchment area on sun safety behaviors.
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
SEATTLE — March 1, 2024 — Fred Hutchinson Cancer Center announced 12 recipients of the 2024 Harold M. Weintraub Graduate Student Award, which recognizes exceptional achievement in graduate studies in the biological sciences. This year’s recipients come from U.S. and international research institutions with thesis topics that include brain signals related to learning and emotion, bacterial pathogens and health, AI algorithms in rare disease diagnosis and treatment, and immune cells involved in brain tumors.
A team at UC Davis has developed a machine-learning model that can better predict which patients are at greater risk to develop hepatocellular carcinoma.
Howard S. Hochster, MD, FACP, director of the Gastrointestinal Oncology Program and Rutgers Cancer Institute of New Jersey Associate Director for Clinical Research and director of Oncology Research, RWJBarnabas Health shares his recommendations about keeping our attention focused on barriers to health care and preventive services and continuing to educate ourselves and others about colorectal cancer to reduce disparities.
Colorectal cancer (CRC) is on the rise in young adults. Incidences of colorectal cancer in young people (those between their mid-20s and late 50s) has more than doubled since the 1990s. Howard S. Hochster, MD, FACP, director of the Gastrointestinal Oncology Program and Rutgers Cancer Institute of New Jersey Associate Director for Clinical Research and director of Oncology Research, RWJBarnabas Health, shares his thoughts on this trend.
Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development of new strategies to detect or intercept the disease in its earliest stages.
In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.
A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.
In a mini-review published in Cancer Epidemiology, Biomarkers & Prevention, a journal from the American Association for Cancer Research, Moffitt Cancer Center researchers shed light on the significant gaps in understanding and addressing the effects of hurricanes and extreme weather events on biological, psychosocial and clinical outcomes among cancer survivors.
Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.The meeting, supported by L’Institut Servier, will be held in-person (witha virtual attendance option) on April 12, 2024, at the Revere Hotel Boston Common and livestreamed virtually on Medscape’s platform.
MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms. As a result, MD Anderson may incorporate these technologies into its own cell therapy programs as well as make them available for licensing to interested parties.
A researcher at The University of Kansas Cancer Center has received a $930,000 grant from the U.S. Department of Defense to study a new targeted therapy option for people diagnosed with ductal carcinoma in situ (DCIS).
The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.
Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. This expansion is part of ongoing efforts to address the impact of structural and interpersonal racism as a cause of disparities in cancer outcomes in the United States.
The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.
Could the TB vaccine be a new immunotherapy for liver cancer? A UC Davis Health study found that the century-old vaccine reduced tumors and extended survival for mice with liver cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.
A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.
The Scarlet Knights presented a $50,000 check from the Kay Yow Cancer Fund to RWJBarnabas Health and Rutgers Cancer Institute of New Jersey to establish the Rutgers Women’s Basketball Cancer Support Game Plan, which will provide funding assistance for underserved female cancer patients across the State of New Jersey.
Prajakta Adsul, MBBS, PhD, MPH, from UNM Cancer Center attended the White House Cervical Cancer Forum focused on education, prevention, early detection and treatment. The Forum was held in late January.
In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers share data on the efficacy and safety of neoadjuvant chemotherapy for locally advanced penile squamous cell carcinoma, addressing a critical gap in evidence regarding treatment options for this rare and aggressive cancer.
Scientists at the UC Davis School of Medicine may have figured out why some people have trouble digesting sorbitol, a sugar alcohol used in sugar-free gum, mints, candy and other products.
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers in collaboration with Sylvester Comprehensive Cancer Center and groups around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies.
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumors; includes vanguard treatment recommendations involving multimodality treatment for high-risk disease.
Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.
Bo (Bonnie) Qin, PhD, researcher and cancer epidemiologist in the Section of Cancer Epidemiology and Health Outcomes at Rutgers Cancer Institute of New Jersey, has received $1.1M from the American Cancer Society to support her research on the impact of lifestyle patterns, social determinants of health, and inflammatory mechanisms on breast cancer survivorship among Black women.
Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a total of $2.6M to support his research on acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that affects both children and adults.
UC Davis Health has adopted a new technology platform, Viz.ai, to help quickly identify patients suspected of having a stroke. The hospital is the first in the Sacramento region to use the platform.
George Raptis, MD, MBA, begins role at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health as director of Oncology Services for the Northern Region of New Jersey.
Today, Memorial Sloan Kettering Cancer Center (MSK), in collaboration with Miami-based creative agency Alma, launched a bilingual public service campaign to promote the importance of routine cancer screenings.
A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.
The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.
For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
